Special Issue "Herpesvirus Infections in the Brain"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Infectious Diseases".

Deadline for manuscript submissions: closed (25 August 2019).

Special Issue Editor

Prof. Dr. Trine Mogensen
E-Mail Website
Guest Editor
Department of Infectious Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark; Department of Biomedicine, Aarhus University, Wilhelm Meyers Alle 4, 8000 Aarhus C, Denmark; Department of Clinical Medicine, Aarhus University, Palle Juul Jensens Boulevard 82, 8200 Aarhus N, Denmark
Interests: Genetic and immunological basis of severe infectious diseases

Special Issue Information

Dear Colleagues,

In recent years, it has emerged that mutations in genes encoding proteins of innate or cell-intrinsic immunity may underlie rare primary immunodeficiencies in humans. Seminal advances have been made in the identification and functional immunological characterization of novel genetic defects predisposing to severe viral infections with herpesviruses, such as HSV-1, HSV-2, VZV, and HHV6. There is now solid evidence to support a role for these herpesviruses not only in causing meningitis and encephalitis, but also in the development of certain autoimmune and neurodegenerative conditions, such as multiple sclerosis and Alzheimer’s disease. These novel insights have been gained through studies on basic epidemiology, genetics, virology, and immunology on the one hand, and the identification of patients with a rare but severe infectious phenotypes, who may directly benefit from our findings in terms of choosing optimal prophylactic and treatment strategies on the other hand. This Special Issue will focus on medically important herpesviruses and describe the basic virology, immune evasion, and immunology relevant for these viruses to gain knowledge of the pathogenesis of severe viral infections in the central nervous system (CNS) and how this knowledge may be used to improve diagnosis, prophylaxis, and treatment of patients.

Prof. Dr. Trine Mogensen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Herpesvirus
  • Encephalitis
  • Innate immunology
  • Interferon
  • CNS inflammation
  • Inborn errors of immunity
  • Immune evasion
  • Autophagy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Gold Nanoparticles Crossing Blood-Brain Barrier Prevent HSV-1 Infection and Reduce Herpes Associated Amyloid-βsecretion
J. Clin. Med. 2020, 9(1), 155; https://doi.org/10.3390/jcm9010155 - 07 Jan 2020
Abstract
Infections caused by HSV-1 and their typical outbreaks invading the nervous system have been related to neurodegenerative diseases. HSV-1 infection may deregulate the balance between the amyloidogenic and non-amyloidogenic pathways, raising the accumulation of amyloid-β peptides, one of the hallmarks in the neurodegenerative [...] Read more.
Infections caused by HSV-1 and their typical outbreaks invading the nervous system have been related to neurodegenerative diseases. HSV-1 infection may deregulate the balance between the amyloidogenic and non-amyloidogenic pathways, raising the accumulation of amyloid-β peptides, one of the hallmarks in the neurodegenerative diseases. An effective treatment against both, HSV-1 infections and neurodegeneration, is a major therapeutic target. Therefore, gold nanoparticles (NPAus) have been previously studied in immunotherapy, cancer and cellular disruptions with very promising results. Our study demonstrates that a new NPAus family inhibits the HSV-1 infection in a neural-derived SK-N-MC cell line model and that this new NPAus reduces the HSV-1-induced β-secretase activity, as well as amyloid-β accumulation in SK-APP-D1 modifies cell line. We demonstrated that NPAuG3-S8 crosses the blood-brain barrier (BBB) and does not generate cerebral damage to in vivo CD1 mice model. The NPAuG3-S8 could be a promising treatment against neuronal HSV-1 infections and neuronal disorders related to the Aβ peptides. Full article
(This article belongs to the Special Issue Herpesvirus Infections in the Brain)
Show Figures

Graphical abstract

Back to TopTop